Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Dry and Wet Age-Related Macular Degeneration – Access & Reimbursement – Access & Reimbursement – Age-Related Macular Degeneration (US)
The age-related macular degeneration (AMD) therapy market in the United States is unique because the market penetration of approved branded therapies—Roche / Genentech’s Lucentis, Regeneron’s…
Urticaria | Treatment Algorithms: Claims Data Analysis | Chronic Inducible Urticaria | US | 2024
Chronic inducible urticaria (CIndU) encompasses various chronic urticaria subtypes caused by specific triggers. CIndU seems to be more resistant than chronic spontaneous urticaria (CSU) to standard…
Urticaria | Treatment Algorithms: Claims Data Analysis | Chronic Spontaneous Urticaria | US | 2024
The drug market for chronic spontaneous urticaria (CSU; previously known as chronic idiopathic urticaria) is dominated by oral medications, including those approved (e.g., first- and second-…
Atopic Dermatitis / Atopic Eczema – Current Treatment – Treatment Algorithms: Claims Data Analysis – Pediatric (US)
Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by relapsing dry, red, and itchy skin. It typically develops in early childhood and can persist into adulthood. The…
Dry and Wet Age-Related Macular Degeneration – Current Treatment – Treatment Algorithms: Claims Data Analysis – Dry and Wet Age-Related Macular Degeneration (US)
The treatment of wet AMD in the United States has been mainly dominated by three anti-VEGF therapies: Roche / Genentech’s off-label Avastin, Roche / Genentech’s Lucentis, and Regeneron’s…
Urticaria | Treatment Algorithms: Claims Data Analysis | Chronic spontaneous urticaria | US | 2023
The drug market for chronic spontaneous urticaria (CSU; previously known as chronic idiopathic urticaria) is dominated by oral medications, including those approved (e.g., first- and second-…
Dry and Wet Age-Related Macular Degeneration – Special Topics – Special Topics: Gene Therapies in Ophthalmology (US)
The wet age-related macular degeneration (AMD) market in the United States is replete with intravitreal (IVT) therapies—including Regeneron’s Eylea, Roche / Genentech’s Lucentis and Vabysmo,…
Dry and Wet Age-Related Macular Degeneration | Disease Landscape & Forecast | G7 | 2023
Age-related macular degeneration (AMD) is a degenerative and progressive ocular disease that diminishes central visual acuity as a result of photoreceptor degeneration in the macula. The wet AMD…
Dry and Wet Age-Related Macular Degeneration – Geographic Focus: China – Dry and Wet Age-Related Macular Degeneration – China In-Depth (China)
Age-related macular degeneration (AMD), which includes dry and wet AMD, is a leading cause of irreparable vision loss globally. In China, patients with wet AMD are typically treated with VEGF…
